Advances in the treatment of hypereosinophilic syndromes / 国际儿科学杂志

ABSTRACT

Hypereosinophilic syndromes(HES)are a heterogeneous group of disorders characterized by persistent overproduction of eosinophils in bone marrow, peripheral blood, and tissues, which can involve multiple tissues and organs at the same time.Eosinophils infiltration and medium release can lead to multiple organ damage.The choice of treatment options depend on clinical manifestations, laboratory test results, and mutation analysis.The purpose of this review is to summarize the current treatment of HES, including conventional therapies such as glucocorticoids, hydroxylurea, interferon-alpha, as well as small molecule targeted drugs led by tyrosine kinase inhibitors, interleukin-5 and its receptor targeted monoclonal antibodies.